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Abstract
The aim of this study was to validate the kilovoltage X-ray energy spectrum on the ID17 beamline at the
European Synchrotron Radiation Facility (ESRF). The purpose of such validation was to provide an accurate
energy spectrum as the input to a computerized treatment planning system, which will be used in synchrotron
microbeam radiotherapy trials at the ESRF. Calculated and measured energy spectra on ID17 have been
reported previously but recent additions and safety modifications to the beamline for veterinary trials
warranted a fresh investigation. The authors used an established methodology to compare X-ray attenuation
measurements in copper sheets (referred to as half value layer measurements in the radiotherapy field) with
the predictions of a theoretical model. A cylindrical ionization chamber in air was used to record the relative
attenuation of the X-ray beam intensity by increasing thicknesses of high-purity copper sheets. The authors
measured the half value layers in copper for two beamline configurations, which corresponded to differing
spectral conditions. The authors obtained good agreement between the measured and predicted half value
layers for the two beamline configurations. The measured first half value layer was 1.754 +/- 0.035 mm Cu and
1.962 +/- 0.039 mm Cu for the two spectral conditions, compared with theoretical predictions of 1.763 +/-
0.039 mm Cu and 1.984 +/- 0.044 mm Cu, respectively. The calculated mean energies for the two conditions
were 105 keV and 110 keVand there was not a substantial difference in the calculated percentage depth dose
curves in water between the different spectral conditions. The authors observed a difference between their
calculated energy spectra and the spectra previously reported by other authors, particularly at energies greater
than 100 keV. The validation of the beam spectrum by the copper half value layer measurements means the
authors can provide an accurate spectrum as an input to a treatment planning system for the forthcoming
veterinary trials of microbeam radiotherapy to spontaneous tumours in cats and dogs.
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The aim of this study was to validate the kilovoltage X-ray energy spectrum on
the ID17 beamline at the European Synchrotron Radiation Facility (ESRF).
The purpose of such validation was to provide an accurate energy spectrum as
the input to a computerized treatment planning system, which will be used in
synchrotron microbeam radiotherapy trials at the ESRF. Calculated and
measured energy spectra on ID17 have been reported previously but recent
additions and safety modifications to the beamline for veterinary trials
warranted a fresh investigation. The authors used an established methodology
to compare X-ray attenuation measurements in copper sheets (referred to as
half value layer measurements in the radiotherapy field) with the predictions of
a theoretical model. A cylindrical ionization chamber in air was used to record
the relative attenuation of the X-ray beam intensity by increasing thicknesses of
high-purity copper sheets. The authors measured the half value layers in copper
for two beamline configurations, which corresponded to differing spectral
conditions. The authors obtained good agreement between the measured and
predicted half value layers for the two beamline configurations. The measured
first half value layer was 1.754  0.035 mm Cu and 1.962  0.039 mm Cu for the
two spectral conditions, compared with theoretical predictions of 1.763 
0.039 mm Cu and 1.984  0.044 mm Cu, respectively. The calculated mean
energies for the two conditions were 105 keV and 110 keV and there was not a
substantial difference in the calculated percentage depth dose curves in water
between the different spectral conditions. The authors observed a difference
between their calculated energy spectra and the spectra previously reported by
other authors, particularly at energies greater than 100 keV. The validation of
the beam spectrum by the copper half value layer measurements means the
authors can provide an accurate spectrum as an input to a treatment planning
system for the forthcoming veterinary trials of microbeam radiotherapy to
spontaneous tumours in cats and dogs.
1. Introduction
Pre-clinical microbeam radiation therapy (MRT) studies have
been performed on the ID17 beamline at the European
Synchrotron Radiation Facility (ESRF) in Grenoble, France,
for approximately ten years. For most of these studies,
researchers have used tumour-inoculated rodents as the
experimental subject (Bouchet et al., 2010, 2013; Serduc et al.,
2009; Laissue et al., 2007; Miura et al., 2006). There has also
been a significant amount of dosimetry work published
ISSN 1600-5775
# 2015 International Union of Crystallography
pertaining to MRT (Prezado et al., 2011; Nettelbeck et al.,
2009; Siegbahn et al., 2006; Brauer-Krisch et al., 2003, 2005).
The pre-clinical studies have shown very promising tumour
control with minimal normal tissue complications. To this end,
veterinary trials of cats and dogs bearing spontaneous tumours
have now begun.
Radiation safety precautions for the veterinary clinical
trials have necessitated the use of additonal ionization
chambers and gas-filled flight pipes. The overall effect is to
reduce the very high incident dose rate and to harden the
X-ray beam relative to the pre-clinical energy spectrum
condition. A computerized treatment planning system (TPS)
for MRT trials using a fast analytical dose calculation algo-
rithm is also under development (Bartzsch & Oelfke, 2013).
The TPS requires the energy spectrum of the synchrotron-
generated X-ray beam as an input. The energy spectrum of a
kilovoltage X-ray beam has a direct influence on the dosi-
metric properties such as the depth of penetration of the beam
and the range of scattered secondary electrons. Knowledge of
the energy spectrum is important for both broad beam and
microbeam radiotherapy studies. The aim of this current study
is to provide an accurate energy spectrum as input to the MRT
treatment planning system.
The energy spectrum of the pre-clinical beam on ID17 was
previously measured using a powder diffraction technique and
this spectrum was subsequently reported in other publications
(Siegbahn et al., 2006). Martı́nez-Rovira et al. recently
reported calculated energy spectra for ID17 at different
positions along the beamline (Martı́nez-Rovira et al., 2012).
They used a combination of the SHADOW ray-tracing code
(Sanchez del Rio et al., 2011) and the PENELOPE Monte
Carlo package (Sempau et al., 2011; Salvat et al., 2009) in their
paper. Given the various modifications to the beamline in
preparation for the veterinary trials, it was considered prudent
to verify the energy spectrum, but a complicated powder
diffraction method was not possible owing to beam time and
staffing constraints. In a recent publication, Crosbie et al.
reported a straightforward method to validate a synchrotron
X-ray beam spectrum by measuring the attenuation of X-ray
intensity (air kerma rate) by copper sheets (the half value
layer method) and comparing with a theoretical model
(Crosbie et al., 2013). The theoretical model uses the
SPECTRA program (Tanaka & Kitamura, 2001) to simulate
the energy spectrum for a given set of input parameters. The
model also uses a MATLAB-based program called
Dose4IMBL, originally developed for the Australian
Synchrotron. The Dose4IMBL program takes the SPECTRA-
generated spectrum and extracts a variety of theoretical
dosimetric information such as half value layers and mean
energy and allows quick comparisons between measured and
theoretical data. In essence, this paper extends the work of
Crosbie et al. (2013) by applying the established methodology
to half value layer measurements taken on the ID17 beamline.
We did not measure the ID17 energy spectrum but rather
validated a calculated spectrum using attenuation measure-
ments.
2. Materials and methods
The ESRF in Grenoble, France, is a third-generation electron
synchrotron with an operating electron energy of 6 GeV and
43 active beamlines. The ESRF has been in general operation
since 1994 and is Europe’s brightest source of synchrotron
X-rays. The maximum storage ring current is 200 mA and the
circumference of the storage ring is 844 m.
2.1. The ID17 beamline
The ID17 beamline at the ESRF has been described in
detail in several publications (Brauer-Krisch et al., 2010;
Nettelbeck et al., 2009; Bravin, 2007); the 2012 and 2014
papers by Martı́nez-Rovira et al. and Cornelius et al. are
perhaps the most comprehensive published descriptions of the
beamline to date (Martı́nez-Rovira et al., 2012; Cornelius et al.,
2014). Briefly, the source of the X-rays is a permanent-magnet
wiggler, 1.5 m long, with a nominal magnetic field of about
1.6 T for a wiggler gap of 24.8 mm, used for the MRT studies.
The synchrotron X-ray beam is transported in vacuo a
distance of about 37 m from the source whereupon the beam
enters an experimental hutch. The sample stage is located
approximately 40 m from the source.
There are several in vacuo and ex vacuo absorbers in the
beam path which serve to filter the energy spectrum. We
consider two conditions: condition 1 corresponding to the pre-
clinical conditions and condition 2 corresponding to the
veterinary trial conditions, requiring the presence of addi-
tional items for safety reasons and decreasing the typical dose
rate of approximately 70 Gy s1 mA1 to about 40 Gy s1
mA1. For condition 1, the following in vacuo filters are in use:
carbon (1.15 mm), aluminium (1.78 mm), beryllium (2.3 mm)
and copper (1.04 mm). These filters harden the X-ray photon
beam and remove low-energy photons (less than 30 keV).
Condition 1 corresponds to the standard condition for pre-
clinical MRT experiments in rodents and in fact has been the
default configuration for several years. Condition 2 is used
during the MRT veterinary trials and uses the same in vacuo
filters as condition 1 plus the following additional filtration:
a 2.2 m-long krypton gas pipe (maintained at an effective
pressure of 85 mbar) (Requardt et al., 2013), two redundant
in vacuo Compton chambers (designed and built at the ERSF)
comprising four aluminium electrodes (each one 0.5 mm
thick) which are coated with gold (between 0.8 and 1.6 mm
thick) (Berkvens et al., 2013), and two redundant in-air
monitoring ionization chambers (Bragg-peak ionization
chambers; model 34070, PTW, Freiburg, Germany) with an
equivalent PMMA thickness of 19 mm (PTW, personal
communication). The Kr gas filter is designed to prevent an
overexposure by absorbing the low-energy photons in the
unlikely event of sudden failure (cracking) of the filters. The
two redundant Compton chambers monitor the incident broad
beam; their signals are cross-calibrated against the measured
absolute dose. The two in-air Bragg peak ion chambers
monitor the accumulated dose during the treatment,
comparing the expected integrated dose every 500 mm of
research papers
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vertical translation of the goniometer movement with the
measured dose increment.
2.2. Energy spectra calculation
The raw and filtered energy spectra were calculated using
the SPECTRA program (version 9.0) (Tanaka & Kitamura,
2001) and the XOP program (version 2.3) (Sanchez del Rio &
Dejus, 2004). These two programs use an analytical approach
to calculating the energy spectra. We used the most accurate
estimates of the storage ring and radiation source (wiggler)
parameters by consulting with the ESRF’s machine control
group. These parameters are shown in Fig. 1, a screenshot
from the SPECTRA program. For the purposes of the calcu-
lation, we assumed the operating mode of the synchrotron was
the so-called 7/8 + 1 filling mode; a train of 868 bunches (7/8 of
the storage ring circumference) filled with 200 mA. The bunch
length in millimetres is given by z. The horizontal and vertical
emittance of the electron beam in milliradians are given by "x
and "y, respectively. The ID17 beamline is a low- beamline
and the values of the beta functions x and y and the
dispersion functions x and y are shown in the screenshot.
The inverse Lorentz factor for the electron beam is given by
1= and the electron beam dimensions, in micrometres, are
given by x and y.
The permanent-magnet wiggler on ID17 has 10  15 cm
periods with a total length of 1.5 m. The wiggler comprises 21
magnetic poles arranged as ten pairs of poles with an addi-
tonal 11th pole which is not included in the calculation. The
wiggler magnetic field B in the peak direction (By) is perhaps
the most important variable when calculating energy spectra.
The magnetic field determines the deflection parameter K. A
double exponential model was used to interpolate previously
measured wiggler-gap magnetic field values. The magnetic
field at 24.8 mm wiggler gap was calculated to be 1.595 T. The
SPECTRA and XOP programs allow the user to select the slit
dimensions: X mm  Y mm, and a calculation point at an
arbitrary distance from the source. We chose 10 mm 0.5 mm
at a distance of 40 m from the source. Both programs allow the
user to calculate the effect of filters or absorbers on the beam
energy spectrum. The user can enter elemental and material
composition data (thickness, density) for the absorbers
(filters) which attenuate the beam according to published
tables from the National Institute of Standards and Tech-
nology (NIST).
2.3. Experimental measurements
The principal technique employed in this study was the half
value layer (HVL) method, using high-purity copper sheets.
The HVL is defined as the thickness required to reduce the
intensity (air kerma rate) of an X-ray beam to 50% of its
original unattenuated value. The HVL technique is straight-
forward and routinely used in clinical radiotherapy dosimetry
protocols in order to assess the energy of the X-ray beam in
terms of millimetres of Cu (or Al). The penetrating properties
of the beam were measured by conducting transmission
measurements through copper sheets, and characterized by
the first to third HVLs. We used high-purity copper (99.9% by
weight) sheets measuring 100 mm  100 mm with total
thicknesses from 0.1 to 8.4 mm (Gammex 116 HVL attenuator
set; Gammex Inc., Middleton, WI, USA). These sheets were
placed normal to the beam. We used the PTW PinPoint ioni-
zation chamber (model No. 31014, PTW, Freiburg, Germany)
to measure the transmitted signal. The PinPoint chamber is a
small-volume cylindrical ionization chamber with an inner
diameter of 2 mm and a sensitive volume of 0.015 cm3. The ion
chamber was connected to a PTW UNIDOS Webline Elec-
trometer operating at a bias voltage of +400 V. The ion
chamber (placed in air) was aligned parallel to the X-ray
beam, which propagates horizontally into the experimental
hutch. We used narrow-beam geometry conditions to just
cover the ion chamber, thus ensuring the chamber only
samples the primary fluence and not any extraneous scattered
radiation (Khan, 2003). The horizontal and vertical beam
dimensions were 10 mm  0.5 mm and the chamber was
moved vertically through the beam in order to simulate a
uniform exposure to a quasi-10 mm 10 mm field size. We did
not observe any statistically significant ion chamber stem
effects in this study. The HVL technique is a relative
measurement, therefore conversion to absolute air kerma rate
in Gy s1 is not necessary, nor is correction for standard
temperature and pressure a requirement. We took three
readings for each copper thickness and averaged the reading.
The readings were normalized to a storage ring current of
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Figure 1
A screenshot from the SPECTRA program showing all parameters for
the storage ring and wiggler radiation source for the ID17 beamline at
the ESRF.
200 mA. We assigned a total uncertainty of 2% to the ion
chamber measurements, based largely on our previous
experience (Crosbie et al., 2013). The relative air kerma rate
electrometer readings at each copper thickness (Kt) were
normalized to the unattenuated zero copper thickness value
(K0). We took the negative logarithm of Kt =K0, which is equal
to a ray-sum, and plotted this ray sum as a function of
absorber thickness. More formally, the log of the ratio of
measured air kerma rate Kt to that for zero absorber thickness
K0 can be expressed as a function of the ray-sum,
 ln
Kt
K0
 
¼
X
L
t; ð1Þ
where the left-hand side is a function of two measured
quantities, and the right-hand sum is the ray sum, equal to the
sum of the product of attenuation coefficients and thickness
for attenuating structures averaged across the beam area and
along line L denoting the path of the ray. We can plot the ray
sum (RS) as a function of thickness, describe the curve using a
polynomial and solve for thickness x. An easier method uses
the same functional model, but changes the variables around
so that thickness is expressed as a function of the ray-sum,
x ¼ a0 þ a1RSþ a2RS
2: ð2Þ
In the present case, we work with the normalized air kerma
rate Kt =K0, so that K0 = 1.0 and, since lnðK0Þ is zero, then so is
parameter a0 (i.e. the curve passes through the origin). We use
curve-fitting routines to find parameters a1 and a2, noting that
higher-order coefficients are not required.
2.4. Comparison with theory
We used a MATLAB-based computer program called
Dose4IMBL originally created for use on the Australian
Synchrotron’s Imaging and Medical Beamline. The mathe-
matics behind Dose4IMBL are described by Crosbie et al.
(2013) and will not be repeated here. Dose4IMBL reads in the
SPECTRA-generated data file and extracts a variety of dosi-
metric information from the calculated energy spectra.
Dose4IMBL is currently limited to only recognizing
SPECTRA-generated files and not XOP data files; therefore
all analysis of HVL and mean energy was done on the
SPECTRA-generated data files. For a heterogeneous beam
the first, second and third HVLs are defined as the thicknesses
of filter material that reduces the air kerma rate K to 50%,
25% or 12.5% of its original value K0, respectively. Having the
air kerma expressed as a function of filter thickness made it a
straightforward process to plot the function and extract the
value for which ln ðK=K0Þ = ln(0.5), ln(0.25) or ln(0.125) and
compare the experimental HVLs with predicted HVLs. The
relative uncertainty in predicted HVL is dominated by
uncertainties in atomic cross sections, particularly at energies
less than 30 keV. Gerward described uncertainties greater
than 3% at 5–25 keV and 1–2% at higher energies (Gerward,
1993). We assigned a conservative uncertainty of 2% in en,
the mass energy absorption coefficient. We also assigned an
uncertainty in the in vacuo filter thickness (0.5%) and filter
orientation (0.8%). Since these error contributions are
uncorrelated, they are combined in quadrature giving a total
relative error for the theoretical HVL of 2.2%. The mean
energy of the beam was estimated assuming an energy-inte-
grating detector. In simple terms, Dose4IMBL sums the
product of energies and fluxes and divides by the fluxes to
arrive at a mean energy [equation (15) of Crosbie et al.
(2013)]. Dose4IMBL also calculates the predicted percentage
depth dose in water by multiplying the theoretical air kerma
rate by an exponential attenuation factor [equation (16) of
Crosbie et al. (2013)].
3. Results
The calculated energy spectra for the wiggler-generated X-ray
beam on the ID17 beamline are plotted in Fig. 2. The wiggler
gap was 24.8 mm and the wiggler magnetic field was 1.595 T.
Three spectra are plotted in Fig. 2: the raw (unfiltered) spec-
trum, the pre-clinical spectrum and the veterinary spectrum
corresponding to the different configurations of beam filtering.
The pre-clinical spectrum is dominated by 1.04 mm of in vacuo
Cu, which removes soft X-rays below 30 keV. The veterinary
spectrum includes two Bragg-peak ionization chambers which
together were modelled as 19 mm of PMMA and had a
marked effect on beam hardening and photon flux. The other
absorbers in the path of the veterinary beam, i.e. the Kr gas
pipe and the redundant Compton chambers (0.0016 mm Au
and 2.0 mm Al), had very little effect on the spectra compared
with the pre-clinical spectra (data not shown). The peak
energies for the pre-clinical and veterinary configurations
were 88 keV and 94 keV, respectively. The mean energies of
the pre-clinical and veterinary configurations were 105 keV
and 110 keV, respectively.
Fig. 3 shows a ray sum plot for the transmission of X-rays
through the copper absorbers for the pre-clinical (Fig. 3a) and
veterinary (Fig. 3b) X-ray beams. We obtained good agree-
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Figure 2
SPECTRA-calculated energy spectra for (a) the raw unfiltered X-ray
beam from the ID17 wiggler, (b) the pre-clinical beam, dominated by
1.04 mm of Cu, and (c) the veterinary beam, which includes two Bragg-
peak ionization chambers in the beam path, modelled as 19 mm of
PMMA.
ment between measurement and theory for the pre-clinical
spectra. Table 1 provides a summary of the measured and
theoretical HVLs. The measured first HVL was 1.754 
0.035 mm Cu and 1.962  0.039 mm Cu for the two spectral
conditions, compared with theoretical predictions of 1.763 
0.039 mm Cu and 1.984  0.044 mm Cu, respectively. The
agreement between measurement and theory was not as good
for the veterinary spectra but the deviation of the curves was
within the limits of the error bars. The deviation was most
marked for the third HVL.
We obtained excellent agreement between the SPECTRA
and XOP codes as can be seen in the plots in Fig. 4 for the pre-
clinical beams, normalized to their maximum values. We
obtained moderate agreement between the SPECTRA/XOP-
calculated energy spectra and the previously reported spectra:
Fig. 2 of Siegbahn et al. (2006) and the vertical slit position
from Fig. 3 of Martı́nez-Rovira et al. (2012). The deviations
between the spectra were most pronounced at energies
greater than 100 keV. There was also a systematic shift at
lower energies (30–50 keV) between the SPECTRA/XOP-
calculated energy spectra and the powder diffraction spectrum
reported by Siegbahn et al.. There was less of a shift in energy
for the Martı́nez-Rovira et al. spectra, but poorer agreement at
the higher energies. The SPECTRA and XOP codes produce
a photon flux in units of photons s1 (0.1% bandwidth)1. In
other words the flux is reported in discrete bins of varying
dimension as the energy increases (Tanaka & Kitamura, 2001;
Sanchez del Rio & Dejus, 2004). We therefore divided the
SPECTRA and XOP-produced photon flux by their energy in
order to make a more meaningful comparison between the
Siegbahn et al. and the Martinez-Rovira et al. energy spectra.
Fig. 5 shows a plot of the percentage depth dose (PDD)
curve in water for the SPECTRA-calculated beam config-
urations. The PDD in water is an important dosimetric para-
meter, particularly when one is commissioning a treatment
planning system. The two plots in Fig. 5 show that in fact there
is not a large difference in PDD properties for the two beam
configurations. The veterinary configuration was slightly more
penetrating in water than the pre-clinical beam and these
differences were most noticable in the 5–15 cm depth range.
4. Discussion and conclusions
We have shown in this paper our ability to validate a calcu-
lated energy spectrum on the ID17 beamline using a simple
research papers
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Table 1
Experimentally measured HVLs compared with theoretical predictions
from the Dose4IMBL program for the pre-clinical and veterinary energy
spectral conditions on ID17.
Pre-clinical Experiment (mm Cu) Theory (mm Cu)
HVL1 1.754  0.035 1.763  0.039
HVL2 2.550  0.051 2.618  0.057
HVL3 3.212  0.064 3.278  0.072
Veterinary Experiment (mm Cu) Theory (mm Cu)
HVL1 1.962  0.039 1.984  0.044
HVL2 2.747  0.055 2.835  0.063
HVL3 3.361  0.067 3.476  0.076
Figure 4
SPECTRA and XOP-calculated energy spectra for the pre-clinical X-ray
beam on ID17 were in close agreement with one another. The energy
spectra from Siegbahn et al. and Martinez-Rovira et al. were different
from the current study, particularly at energies greater than 100 keV.
Figure 3
Ray-sum transmission curves for copper for the pre-clinical (a) and
veterinary (b) spectral conditions showing good agreement between
measured and theoretical values.
X-ray attenuation method. The HVL measurements in copper
are easy to perform and closely agreed with our spectral
calculations. We emphasize we have not measured the energy
spectrum but rather used attenuation measurements to vali-
date a calculated spectrum. The Dose4IMBL program proved
to be a useful tool for quickly assessing the dosimetric effects
of an altered beam spectrum; for example, the pre-clinical and
veterinary configurations on ID17. The methodology reported
here was recently described by Crosbie et al. (2013). The
method relies heavily on knowing exactly what absorbers are
in the path of the beam and the parameters of the storage ring
and radiation source (e.g. wiggler). The ID17 beamline is a
mature beamline at a 20 year old facility; therefore beamline
components and storage ring parameters are well known and
understood. The excellent agreement between measurement
and theory for the pre-clinical configuration (Fig. 3a) is a
testament to this fact. That we observed slightly poorer
agreement for the new veterinary configuration (Fig. 3b)
suggests slight deficiencies in how we modelled the material
composition of the Bragg-peak ionization chambers and the
Compton chambers. For example, the total thickness of the
gold coating on the four aluminium electrodes was best esti-
mated to between 0.8 and 1.6 mm; we used a ’worst-case’
thickness in our calculations. There may also be an uncertainty
on the density of Kr gas within the flight pipe.
The close agreement between the SPECTRA and XOP
codes (Fig. 4) for the pre-clinical configuration was encoura-
ging. In addition, we also obtained near-perfect agreement
when we used an additional in-house energy spectra calculator
code, independently developed by one of the co-authors
(AWS, data not shown).
There is considerable room for future work using differing
operating conditions, e.g. increased wiggler gaps to vary the
energy spectrum and the flux rate. Another area which we
have invested considerable efforts into is the topic of ioniza-
tion chamber correction factors. The linear response of the ion
chamber over the energy range is critical for absolute dosi-
metry, and in fact is the subject of a separate paper by the co-
authors. Two separate correction factors are required here: a
correction for ion recombination (ks) and beam quality (kQ).
The co-authors have unpublished ion recombination data,
obtained using a storage ring current ramping method; the
only reliable way to reduce the dose rate without changing the
energy spectrum. In summary, we observed a maximum value
of ks of 1.047 for the pre-clinical energy configuration. The
beam quality correction factor, kQ, for the PinPoint IC was
stable over the energy range, based on calibration factors from
the PTB primary standards laboratory in Germany (detailed
data not shown). The PTB-supplied kQ values were 0.950
(standard deviation 0.011) and 0.952 (standard deviation
0.015) for two separate PinPoint ion chambers across the
energy range of interest on the ID17 beamline. The stability in
kQ in this energy range was reassuring to us. The details of our
work in ion recombination and energy corrections for absolute
dosimetry are the subject of a separate manuscript.
It is perhaps not too surprising that we did not obtain as
good agreement between the SPECTRA/XOP data and the
powder-diffraction measured spectrum from Siegbahn et al.
and the Monte Carlo-calculated spectra of Martı́nez-Rovira
et al.. These spectra from 2006 and 2012 were obtained via
completely different methods and, in the case of Siegbahn et
al., the powder diffraction techique used to measure the ID17
energy spectra was performed over ten years ago using the
methodology described by Honkimaki & Suortti (1992, 2007).
It is possible that some beamline components (absorbing
filters) and wiggler parameters (magnetic field) were not the
same as the current setup. The shift in low energies for the
2006 spectrum indicates a difference in beam filtration; the
2006 spectrum was shifted towards higher energies compared
with the other spectra, up to around 150 keV whereupon it
overlaps and then diverges from the SPECTRA/XOP data.
The 2012 spectrum more closely resembles our current data at
low energies (less than 100 keV) but had poorer agreement at
higher energies compared with the other spectra. Despite
these differences, it was encouraging to note that the energy
spectra were relatively similar to one another, considering the
different ways they were recorded. Siegbahn et al. quoted the
mean energy of the (pre-clinical) beam to be 107 keV in the
interval 30–600 keV, whereas Martı́nez-Rovira et al. quoted
the mean energy to be 99 keV in the same energy range. These
authors further stated the peak energy was 75 keV and the
final fraction of photons with energies higher than 300 keV
was 0.1%. In our current study, we reported a mean energy
(weighted average) of 105 keV for the pre-clinical configura-
tion, in close agreement with the 2006 mean energy.
The PDD curves in Fig. 5 were quite insensitive to spectral
changes compared with the ray-sum plots (Fig. 3). Whilst the
PDD curves are undoubtedly useful from the perspective of
the treatment planning system, they may not be the best way
to compare different spectral configurations. The validation of
the beam spectrum by the copper HVL measurements means
we can provide an accurate spectrum as an input to a treat-
ment planning system for the veterinary trials of MRT to
spontaneous tumours in cats and dogs. We would advise other
MRT developers around the world to ensure they provide a
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Figure 5
Predicted percentage depth dose (PDD) in water curves as calculated by
the Dose4IMBL program using the pre-clinical and veterinary energy
spectra from Fig. 2.
validated energy spectrum to their planning system. We also
recommend incorporating HVL measurements into a routine
quality assurance program for any synchrotron radiotherapy
trials. Accurate, absolute dose measurements are very
important since any potential errors are propagated through
the treatment planning system to the final dose prescription,
while relative calculations such as the peak-to-valley dose
ratio are rather robust to the small spectral changes. One
could therefore use the same validated (veterinary) spectrum
for any pre-clinical MRT studies.
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François Estève from INSERM U836 Equipe 6 for hosting his
stay as a Visiting Scientist at the ESRF in 2012/2013. MD
acknowledges financial support from the European Union’s
COST Action TD1205. PF and IC were funded by NH&MRC
Development Grant 1017394. The authors thank Drs Imma-
culada Martı́nez-Rovira, Erik Siegbahn and Viejo Honkimäki
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